1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Company
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Real-time Estimate Cboe Europe  -  09:52 2022-06-30 am EDT
502.80 CHF   -0.32%
06/26Lonza Signs License Deal With Adva Biotechnology For Automated Bioreactor-linked Patents
MT
06/24LONZA : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza's Patents
PU
06/15Lonza Group Signs Manufacturing Agreement With Pierre Fabre
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Lonza Group AG
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:

- bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for biopharmaceuticals, drugs and nutrition products;

- fine organic and performance chemical products (28.6%): for food products, hygiene products, beauty products and wood care products, etc.;

- other (1%).

Net sales break down geographically as follows: Switzerland (9.7%), Europe (28.3%), the United States (42.3%), Americas (3.8%), Asia (14.2%), Australia and New Zealand (1.3%), Africa (0.3%) and other (0.1%).

Number of employees : 16 218 people.
Sales per Business
20202021Delta
Biologics--2 699.0049.9%-
Capsules & Health Ingredients--1 204.0022.3%-
Small Molecules--767.0014.2%-
Cell & Gene--602.0011.1%-
Corporate/Eliminations36.000.8%137.002.5% +280.56%
CHF in Million
Sales per region
2021
United States2 117.0040.3%
Switzerland656.0012.5%
Ireland399.007.6%
Rest of Europe218.004.2%
Japan206.003.9%
Belgium202.003.8%
Germany201.003.8%
United Kingdom170.003.2%
China143.002.7%
Sweden142.002.7%
Singapore139.002.6%
Denmark131.002.5%
France97.001.8%
Canada82.001.6%
South Korea79.001.5%
Netherlands76.001.4%
Brazil60.001.1%
Rest of Latin America47.000.9%
Spain44.000.8%
India40.000.8%
CHF in Million
Managers
Name Title Age Since
Pierre-Alain Ruffieux Chief Executive Officer 52 2020
Philippe Deecke Chief Financial Officer 49 2021
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation 55 2007
Dirk Oehlers Investor Relations Officer - 2002
Caroline Barth, Dr. Chief Human Resources Officer - 2020
Members of the board
Name Title Age Since
Albert Baehny Chairman 69 2020
Barbara May Richmond Independent Director 61 2014
Juergen Steinemann Independent Director 63 2014
Christoph Mäder Independent Director 62 2016
Angelica Kohlmann, Dr. Independent Director 60 2018
Olivier Verscheure, Dr. Independent Director 49 2018
Marion Helmes, Dr. Independent Director 55 2022
Roger Nitsch, Dr. Independent Director - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,468,752 74,136,310 99.6% 279,623 0.4% 99.6%
Shareholders
NameEquities%
BlackRock Investment Management (UK) Ltd. 2,396,218 3.22%
The Vanguard Group, Inc. 1,931,851 2.59%
Norges Bank Investment Management 1,778,256 2.39%
Fidelity Management & Research Co. LLC 1,755,840 2.36%
Capital Research & Management Co. (World Investors) 1,441,066 1.94%
UBS Asset Management Switzerland AG 1,156,908 1.55%
Harris Associates LP 1,136,402 1.53%
WCM Investment Management LLC 1,030,592 1.38%
Credit Suisse Asset Management (Schweiz) AG 964,666 1.30%
TIAA-CREF Investment Management LLC 795,245 1.07%
Holdings
NameEquities%Valuation
LONZA GROUP AG (LONN) 279,623 0.38% 168,377,651 USD
AFFINIA THERAPEUTICS INC 4,990,478 8.63% 50 USD
Markets and indexes
- Primary listing
- SMI / STOXX Europe 600
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  LONN.S
- Datastream Code :  
Company contact information
Lonza Group AG
Münchensteinerstrasse 38
CH-4002 Basel, Basel-Stadt

Phone : +41 61 316 81 11
Fax :
web site : http://www.lonzagroup.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Lonza Group AG